In silico Evaluation of Impurities Found in Some Generic Drugs of Piperacillin/ TazobactamShigeru Fujimura1,2*, Takumi Sato1 and Akira Watanabe2
- *Corresponding Author:
- Shigeru Fujimura
Division of Clinical Infectious Diseases & Chemotherapy
Graduate School of Pharmacy, Tohoku Medical and Pharmaceutical University
4-4-1 Komatsushima, Aoba-ku, Sendai, 981-8558, Japan
E-mail: [email protected]
Received date: March 30, 2017; Accepted date: April 13, 2017; Published date: April 20, 2017
Citation: Fujimura S, Sato T, Watanabe A (2017) In silico Evaluation of Impurities Found in Some Generic Drugs of Piperacillin/Tazobactam. J Antimicrob Agents 3:138. doi: 10.4172/2472-1212.1000138
Copyright: © 2017 Fujimura S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Characterization of impurities present in generic antimicrobial agents is not required according to the approval criteria for their sale worldwide. To assess the safety of generics, we conducted a structural estimation of impurities in six piperacillin/tazobactam generics and carried out an in silico analysis. Namely, these generics were compared with the brand name drug by HPLC and LC-MS. The mutagen that in silico analysis showed alert was detected in five of six generic products. It was estimated that this mutagen was an azido group of the precursor used in the synthesis process of tazobactam whose patent has expired. With regards to this mutagenic substance, pharmaceutical companies marketing a generic Piperacillin/Tazobactam product will have to check presence or absence of this mutagen before introducing the product to the market.